简介：Aims: Treatment-experienced genotype (GT) 2/3 HCV-infected patients have poor response rates to retreatment with peginterferon (PEG) + ribavirin (RBV). We report here the results from FUSION， a Phase 3 study designed to evaluate sofosbuvir (SOF) 400mg QD+ RBV 1000-1200mg for 12 or 16 weeks in treatment-experienced GT2/3 HCV-infected patients.